Liquidia showcases PRINT vaccine technology at conference

Liquidia Technologies showcased the diverse abilities of its PRINT (Particle Replication In Non-Wetting Templates) technology in vaccine development at the 15th World Vaccines Congress this week in Washington, D.C.

PRINT technology involves particle engineering and enables Liquidia to accurately tailor a specific particle’s shape, size, hydrophobicity, charge and composition. These specifics impact the vaccine’s ability to provoke an immune response from the human body.

Liquidia has used its PRINT technology to create specialized particle systems that provoke an enhanced cellular and humoral immune response from the human body. This was accomplished through a variety of matrix materials with adjuvants and antigens.

At present, Liquidia is using PRINT technology for solutions to problems that are often raised in the vaccine-development industry. Company leaders said the ultimate goal is to make vaccines that are safe and effective, and that provide the widest range of protection for the world’s populations.

Dr. Michele Stone, executive director of vaccines at Liquidia Technologies, presented the information under the title “Utilizing PRINT Technology to Advance Vaccine Development.”

Organizations in this Story

Liquidia Technologies

Want to get notified whenever we write about Liquidia Technologies ?
Next time we write about Liquidia Technologies, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.